TABLE 1.
Baseline | Intervention with 5 mg FA/d
|
P | ||
---|---|---|---|---|
45 d | 90 d | |||
Serum folate, 2 nmol/L | 17.1 (15.1–19.5)a | 81.7 (71.9–92,9)b | 84.5 (74.4–96.2)b | <0.001 |
Serum total folate, 3 nmol/L | 22.6 (20.2–25.4)a | 97.1 (86.6–108.9)b | 100.1 (89.2–112.2)b | <0.001 |
Serum UMFA,3 nmol/L | 0.57 (0.51–0.64)a | 3.86 (2.94–5.28)b | 2.21 (1.79–2.79)b | <0.001 |
Serum 5-methyl-THF,3 nmol/L | 22.5 (18.9–26.5)a | 75.8 (68.1–83.9)b | 83.8 (76.8–91.0)b | <0.001 |
Serum THF,3 nmol/L | 0.40 (0.32–0.49)a | 0.94 (0.69–1.22)b | 1.19 (1.02–1.32)b | <0.001 |
Serum MeFox,3 nmol/L | 0.70 (0.57–0.85)a | 1.67 (1.36–2.04)b | 1.65 (1.42–1.92)b | <0.001 |
High serum folate, (>45.0 nmol/L), n (%) | ||||
Microbiologic assay | 1 (3.3)a | 28 (93.3)b | 28 (93.3)b | <0.0014 |
HPLC/MS-MS | 2 (6.6)a | 30 (100)b | 30 (100)b | <0.0014 |
High serum UMFA,3 (> 1.12 nmol/L) | 2 (6.6)a | 29 (96.6)b | 26 (86.7)b | <0.0015 |
Serum vitamin B12,2 pmol/L | 376 (334–421) | 364 (327–403) | 387 (342–434) | 0.332 |
Plasma total homocysteine,6 μmol/L | 8.4 (7.6–9.3) | 8.1 (7.4–8.9) | 8.0 (7.2–8.8) | 0.394 |
Values are means and 95% CIs of back-transformed values unless otherwise indicated. Serum 5,10-methenyl-THF and 5-formyl-THF were below the limit of detection (0.2 nmol/L). Numeric variables were transformed by Box-Cox, and the data are presented after reconversion.
One-factor repeated-measures ANOVA was used; when significant, Tukey’s test was performed. Labeled means in a row without a common superscript letter differ, P < 0.05. FA, folic acid; HPLC-MS/MS, HPLC–tandem MS; MeFox, oxidation product of 5-methyl-THF; THF, tetrahydrofolate; UMFA, unmetabolized folic acid.
Derived by using a microbiological assay.
Derived by using HPLC-MS/MS.
Derived by using likelihood ratios.
Derived by using chi-square.
Derived by using chemiluminescence.